Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139368 · ClinicalTrials.gov registry record · NA
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
A NA study of Endometrial Carcinoma and Cervical Carcinoma, sponsored by University of Utah.
- Active
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05139368: Active NA study of Endometrial Carcinoma and Cervical Carcinoma, sponsored by University of Utah.
NCT05139368 is a NA study of Endometrial Carcinoma and Cervical Carcinoma that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 22 participants, below the 390-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05139368, a NA study of Endometrial Carcinoma and Cervical Carcinoma, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies the feasibility of using hypo-fractionated radiotherapy for the treatment of cervical or endometrial cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
Primary Outcome
Change in toxicity will be measured by the change in bowel domain score as assessed on the Expanded Prostate Cancer Index Composite (EPIC) instrument. EPIC is a 26-item, self-assessed questionnaire rated on a 5-point Likert scale. 14 items in this assessment create the Bowel Summary score. Bowel Summary scores are transformed linearly to a 0-100 scale, with higher scores indicating better Health-related Quality of Life (HRQOL) and lower scores indicating worse HRQOL. This outcome measure will r
Conditions Studied
Interventions
- RADIATION Hypofractionated Radiation Therapy
Study Locations (1)
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-11-11 |
| Est. Completion | 2027-06-26 |
| Phase | NA |
What the registry record for NCT05139368 still lists
NCT05139368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 390-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Endometrial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Hypofractionated Radiation Therapy is the first listed.
NCT05139368 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05139368 about?
NCT05139368 is a clinical study titled "Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer". This clinical trial studies the feasibility of using hypo-fractionated radiotherapy for the treatment of cervical or endometrial cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effec...
What is the current status of trial NCT05139368?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2021-11-11. Estimated completion is 2027-06-26.
What conditions does trial NCT05139368 study?
This clinical trial studies the following conditions: Endometrial Carcinoma, Cervical Carcinoma.
What interventions are being tested in trial NCT05139368?
The interventions under investigation include: Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05139368?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05139368 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05139368's enrollment target sits among peer trials
22 27th of 27 the lowest of 27 other Endometrial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
RECRUITING · NA
-
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
RECRUITING · NA
-
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
RECRUITING · NA
-
Screening and Staging of Benign vs Malignant Pelvic Abnormalities
RECRUITING
-
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
RECRUITING
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI